Add Ezetimibe (Zetia), Not Fenofibrate
With an LDL of 98 mg/dL and triglycerides of 191 mg/dL on rosuvastatin 20 mg, you should add ezetimibe 10 mg to further reduce LDL-C and cardiovascular risk. Fenofibrate is not indicated in this scenario and may paradoxically increase LDL-C.
Why Ezetimibe is the Right Choice
Your patient's lipid profile shows:
- LDL-C 98 mg/dL: Still above optimal targets for most patients with cardiovascular disease or high risk
- Triglycerides 191 mg/dL: Only mildly elevated (borderline high is 150-199 mg/dL)
The 2018 ACC/AHA guidelines clearly state that in patients with clinical ASCVD on maximally tolerated statin therapy with LDL-C ≥70 mg/dL, it is reasonable to add ezetimibe 1. The 2022 BMJ guideline reinforces this, recommending ezetimibe addition for very high and high-risk patients when LDL-C remains ≥70 mg/dL despite statin therapy 2.
The Evidence for Ezetimibe
Adding ezetimibe 10 mg to rosuvastatin produces substantial additional LDL-C reduction:
- 21% additional LDL-C reduction when added to stable rosuvastatin doses 3
- Ezetimibe + rosuvastatin 10 mg reduces LDL-C by 17.5% more than doubling rosuvastatin to 20 mg 3
- 59.4% of patients reach LDL-C targets with ezetimibe add-on versus only 30.9% with statin dose doubling 3
A 2025 meta-analysis confirmed that moderate-intensity statin plus ezetimibe achieves significantly greater LDL-C reduction (mean difference -6.59 mg/dL) compared to high-intensity statin monotherapy 4.
Why NOT Fenofibrate
Fenofibrate is the wrong choice here for three critical reasons:
1. Triglycerides Are Not High Enough
The FDA label indicates fenofibrate is for severe hypertriglyceridemia (typically >500 mg/dL) or as adjunctive therapy when triglycerides are the primary concern 5. Your patient's triglycerides at 191 mg/dL are only mildly elevated and don't warrant fibrate therapy.
2. Fenofibrate Can INCREASE LDL-C
The FDA label explicitly warns: "Treatment of patients with elevated triglycerides often results in an increase of LDL-C" 5. In clinical trials, patients with baseline LDL >160 mg/dL and TG ≥150 mg/dL who received fenofibrate saw only a 20.1% LDL-C reduction, with some subgroups experiencing LDL-C increases 5. This is counterproductive when your primary goal should be further LDL-C reduction.
3. No Proven Cardiovascular Benefit
The FDA label states clearly: "The effect of fenofibrate on cardiovascular morbidity and mortality has not been determined" 5. The label also notes fenofibrate "was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus" 5.
The Practical Algorithm
For patients on rosuvastatin 20 mg with LDL 70-100 mg/dL:
First-line add-on: Ezetimibe 10 mg 1, 2
- Expect additional 15-25% LDL-C reduction
- Well-tolerated with minimal adverse effects
- Proven cardiovascular benefit when combined with statins
If LDL remains ≥70 mg/dL after statin + ezetimibe:
- Consider PCSK9 inhibitor for very high-risk patients 1
Reserve fenofibrate for:
Key Caveats
- Monitor for myopathy: While rare, statin-ezetimibe combinations are generally safe. The 2025 meta-analysis found no significant increase in adverse events 4
- Don't combine fenofibrate with ezetimibe without a statin: This provides no cardiovascular benefit
- Triglycerides 191 mg/dL contribute minimally to residual risk compared to the LDL-C of 98 mg/dL, which remains the primary modifiable target
- If patient has diabetes: Even then, ezetimibe remains first choice; fenofibrate might be considered only if triglycerides were >200 mg/dL for microvascular benefits 6, 7
The evidence overwhelmingly supports ezetimibe addition in this clinical scenario, with proven LDL-C lowering efficacy and cardiovascular benefit, while fenofibrate offers no advantage and potential harm through LDL-C elevation.